Stents are tubular device used for insertion in lumen such as esophagus, colon or blood vessel. Stents are safe and effective alternative to surgery or repetitive endoscopic procedures. Gastrointestinal stents are used to open bile ducts, esophagus, small bowel, and colon when blocked by large, cancerous tissue growth. Stents can be removable or permanently implantable based on the material used. The role of stenting is decreasing patients’ digestive tract obstruction. Moreover, advancement in technology has led to improvement in stent performance and reduced stent-induced complications to improve quality of life and this is expected to propel the gastrointestinal stent market growth.
Gastrointestinal Stents Market – Market Dynamics
Growth of the global gastrointestinal stents market is expected to be fuelled by increasing product launches with novel technology by key players in the market. For instance, in 2013, Cook Medical Inc. received U.S. Food and Drug Administration (FDA) for biliary stent, adding to the line of controlled-release gastrointestinal tract. Moreover, Evolution biliary stent incorporates patency design, to prevent migration of stent after its insertion. Furthermore, in 2012, Boston Scientific Corporation launched WallFlex, biliary Transhepatic Stent System for the treatment of benign biliary strictures. Companies are focusing on manufacturing stents with biodegradable material to eliminate stent removal procedures. However, implantable products are subjected to stringent regulations, and this is expected to hinder growth of the gastrointestinal stent market. Moreover, complication associated with gastrointestinal stent implantation is also expected to be major factor leading to low adoption of these device.
Increasing demand for minimally invasive procedures is expected to be a major factor driving growth of gastrointestinal stents market size. Gastrointestinal stenting is considered as minimally invasive therapy and is increasingly gaining popularity, owing to its advantages such as low risk of infection, less recovery time as compared to conventional open surgery procedures, and reduced hospital stay.
Increasing prevalence of urological and gastrointestinal disorders are propelling demand of gastrointestinal stents during the forecast period. According to Center for Disease Control and Prevention (CDC), in 2015, number of adults diagnosed in U.S. with ulcer in digestive tract are 14.7 million, comprising 6% of the total adult population. Moreover, according to American Cancer Society’s estimation for year 2018 suggests that 9,220 new cases of colon cancer are expected to be diagnosed in the U.S. Moreover, increasing number of patients with gastrointestinal tumors is also adding to patient pool that can be subjected to gastrointestinal stent implantation.
Gastrointestinal Stents Market - Regional Analysis
Regional segmentation of Gastrointestinal Stents Market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America held the dominant position in the gastrointestinal stents market in 2017 and is expected to retain its dominance over the forecast period. This is owing to increasing number of intestinal cancer cases and favorable reimbursement policies in the region. For instance, in 2017, American Cancer Society estimated 4,000 to 6,000 cases each year in the U.S. for gastrointestinal stromal tumors.
Gastrointestinal Stents Market – Competitive Analysis
Major market players operating in the gastrointestinal stents market are Boston Scientific Corporation, Medtronic plc, Olympus Medical System, Cook Medical, Ella-CS, Endo-Flex, Diagmed Healthcare, Micro-Tech, W. L. Gore & Associates and Taewoong Medical Co., Ltd.
Market players are focusing on inorganic strategies such as mergers, acquisitions, or collaborations to increase their foothold in the market. For instance, in May 2018, Olympus— a company that designs and delivers innovative solutions for medical and surgical procedures—entered into an agreement with M.I. Tech, a company that designs stents and other devices. Under this agreement, HANAROSTENT, biliary and esophagus stents rolled in the EndoTherapy product portfolio of the company. The displacement of the stents is a major issue faced after the stent is been placed. Targeting these issues, in 2017, W. L. Gore & Associates, the manufacturer of Gore Viabil short wire biliary endoprosthesis stent, launched anti-migration assurance program, under which device will be replaced within a period of one year if it migrates. Furthermore, in 2016, Boston Scientific launched AXIOS stent and Electrocautery Enhanced delivery system, endoscopic system used for minimally invasive treatment of pancreatitis, obtained as a part of acquisition of Xlumena. In 2015, Cardinal Health announced acquisition of Cordis, business of Johnson & Johnson, for US$ 1.944 Bn.
Gastrointestinal Stents Market Taxonomy
Based on product type, the gastrointestinal stents market is segmented into:
Based on Material, the gastrointestinal stents market is segmented into:
Based on end user, the gastrointestinal stents market is segmented into:
Based on region, the gastrointestinal stents market is segmented into: